RESUMEN
Context: A large body of literature has shown that forests provide nutritious foods in many low- and middle-income countries. Yet, there is limited evidence on the contributions from different types of forest and tree systems. Objectives: Here, we focus on individual trees and smaller forest patches outside established forest reserves as well as different forest management systems. Methods: We do so by combining novel high-resolution data on tree cover with 24-h dietary recall surveys from 465 women in Tanzania. Results: We show that people with more unclassified tree cover (i.e., individual trees and small forest patches) in their nearby surroundings have more adequate protein, iron, zinc, and vitamin A intakes. We also find that having a nearby forest under Participatory Forest Management (PFM) system is associated with higher adequacy levels of energy, iron, zinc and vitamin A. By contrast, tree cover within other types of forest (e.g., Government Forest Reserves and Government Forest Plantations) is not positively associated with people's dietary quality. Conclusions: Our key finding is that having individual trees, smaller forest patches and/or forest under PFM in close proximity is more beneficial for people's diets than other types of established forests. Our results highlight the nutritional importance of trees outside established forests and question the often-assumed benefits of forests if these are made inaccessible by social barriers (e.g., legislation). Finally, our results emphasize the need to distinguish between different forest management systems when studying forest-diet linkages. Supplementary Information: The online version contains supplementary material available at 10.1007/s10980-024-01961-6.
RESUMEN
We describe here the design and initial implementation of the eMERGE-PGx project. eMERGE-PGx, a partnership of the Electronic Medical Records and Genomics Network and the Pharmacogenomics Research Network, has three objectives: (i) to deploy PGRNseq, a next-generation sequencing platform assessing sequence variation in 84 proposed pharmacogenes, in nearly 9,000 patients likely to be prescribed drugs of interest in a 1- to 3-year time frame across several clinical sites; (ii) to integrate well-established clinically validated pharmacogenetic genotypes into the electronic health record with associated clinical decision support and to assess process and clinical outcomes of implementation; and (iii) to develop a repository of pharmacogenetic variants of unknown significance linked to a repository of electronic health record-based clinical phenotype data for ongoing pharmacogenomics discovery. We describe site-specific project implementation and anticipated products, including genetic variant and phenotype data repositories, novel variant association studies, clinical decision support modules, clinical and process outcomes, approaches to managing incidental findings, and patient and clinician education methods.